Literature DB >> 7876398

Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg.

G Montay1, R Bruno, J C Vergniol, M Ebmeier, Y Le Roux, C Guimart, A Frydman, D Chassard, J J Thebault.   

Abstract

The pharmacokinetics of sparfloxacin at oral doses of 200, 400, 600, and 800 mg were studied in 12 healthy volunteers in a randomized double-blind crossover study. Each dose administration was separated by a 1-week washout period. Plasma and urine samples were collected up to 120 hours postdosing, for determination of free and total (free plus glucurono-conjugated) sparfloxacin levels by high-performance liquid chromatography assay and ultraviolet detection. Mean Cmax values ranged from 705 +/- 158 to 1966 +/- 620 ng/mL for the 200 to 800 mg doses, at median tmax ranging from 4 to 5 hours. A slight decrease of sparfloxacin bioavailability with increasing dose was observed because AUC was 87% to 88% of the expected area when the dose was doubled. The elimination half-life values were constant over the dose range (with values ranging from 18 to 21 hours) as well as the renal clearance. The metabolic ratio conjugated/free drug was not modified by increasing dose.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7876398     DOI: 10.1002/j.1552-4604.1994.tb01983.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  8 in total

1.  Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.

Authors:  J A Zix; H F Geerdes-Fenge; M Rau; J Vöckler; K Borner; P Koeppe; H Lode
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 2.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

Review 4.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials.

Authors:  Aditi Mulgaonkar; Jürgen Venitz; Dirk Gründemann; Douglas H Sweet
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

6.  The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.

Authors:  M Kamberi; H Nakashima; K Ogawa; N Oda; S Nakano
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

Review 7.  Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.

Authors:  K L Goa; H M Bryson; A Markham
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

8.  Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors.

Authors:  E Cormet-Boyaka; J F Huneau; A Mordrelle; P N Boyaka; C Carbon; E Rubinstein; D Tomé
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.